USA Opioids Drug Market Size, Share, Industry, Forecast and outlook (2024-2031)

USA Opioids Drug Market is segmented By Drug Type (Codeine, Oxycodone, Hydrocodone, Fentanyl, Morphine, Hydroxymorphone, Propoxyphene, Others), By Application (Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression, De-addiction), By End-User (Hospitals and Clinics, Academic and Research Centers, Deaddiction Centers, Others) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The U.S. opioids drug market reached US$ 9.58 billion in 2023 and is expected to reach US$ 13.02 billion by 2031, growing at a CAGR of 4.0% during the forecast period 2024-2031.

Opioid drugs are a group of medications known for their potent pain-relieving capabilities. They work on opioid receptors in the brain and nervous system to reduce pain by altering how the body perceives and responds to it. Opioids include prescription pharmaceuticals such as morphine, oxycodone, hydrocodone, and fentanyl, as well as illegal substances like heroin.

 These medications are extremely efficient at treating severe pain, especially in medical contexts such as after surgery or for chronic diseases like cancer. However, opioids carry serious risks and adverse effects. Their use may end in physical dependence, in which the body becomes acclimated to the medication, and withdrawal symptoms if it is lowered or discontinued abruptly.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing prevalence of chronic diseases that result in chronic pain 

The rising prevalence of chronic diseases that result in chronic pain propels the market growth. For instance, according to the National Cancer Institute, In 2024, roughly 2.0 million people will be diagnosed with cancer in the United States. An estimated 310,720 women and 2,790 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis. Prostate cancer is the leading cancer diagnosis among men and the second most common diagnosis overall with 299,010 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis with an estimated 234,580 new cases.

In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. 89,070 new cases of melanoma in situ of the skin are being estimated in 2023. 5,420 males and 2,570 females are estimated to die from melanoma in 2023. 

Restraints

Factors such as adverse effects and risks related to opioids are expected to hamper the market. Symptoms of opioid use include drowsiness, constipation, euphoria, nausea, vomiting, and slowed breathing. A person using opioids over time can develop tolerance, physical dependence, and opioid use disorder, with the risk of overdose and death.

Market Segment Analysis

The USA opioids drug market is segmented based on drug type, application, and end-user.

The segment pain relief accounted for approximately 67.5% of the USA opioids drug market share

The pain relief segment is expected to hold the largest market share over the forecast period. In this segment, the increasing number of treatments that cause severe pain would drive this market.

The opioid drugs offer pain relief from severe pain that is caused due to treatments and surgeries that result in severe pain like chemotherapy in cancer patients and pains caused due to chronic diseases. They activate an area of nerve cells in the brain and body called opioid receptors that block pain signals between the brain and the body.

Opioid medicines travel through the blood and attach to opioid receptors in brain cells. This blocks pain messages and can give relief from severe pain. Opioids mediate both ascending and descending pain pathways. The primary afferent pain fibers are the thinly myelinated A-delta fibers and the unmyelinated C fibers. The endogenous opioids are part of a large, complex system of neurons in the central and peripheral nervous system that exert an analgesic effect on incoming pain stimuli in the spinal cord dorsal horn.

Market Segmentation

By Drug Type

• Codeine
• Oxycodone
• Hydrocodone
• Fentanyl
• Morphine
• Hydroxymorphone
• Propoxyphene
• Others 

By Application

• Pain Relief
• Anesthesia
• Cough Suppression
• Diarrhea Suppression
• De-addiction

By End-User

• Hospitals and Clinics
• Academic and Research Centers
• Deaddiction Centers
• Others

Market Competitive Landscape

The major players in the USA opioids drug market include Pfizer Inc., Purdue Pharma L.P, Johnson & Johnson Services Inc., Hikma Pharmaceuticals PLC, Sanofi, Abbvie Inc., Merck KGaA, Viatris Inc., Teva Pharmaceutical Industries Ltd., and Endo Inc. among others.

Key Developments

•  In January 2022, Trevena, Inc. announced that the Chinese National Medical Products Administration (NMPA) accepted the application of a New Drug Application for oliceridine injection, approved by the Food and Drug Administration in the United States for use in young people for the treatment of chronic pain that is so severe to be treated with an intravenous opioid analgesic.

Why Purchase the Report?

• To visualize the USA opioids drug market segmentation based on drug type, application, and end-user as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of USA opioids drug market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The USA opioids drug market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies